Loading...
Market
Who will be the leading competitor to Vutrisiran in the ATTR amyloidosis market by end of 2025?
2
Alnylam Pharmaceuticals•European Medicines Agency•Vutrisiran•Alnylam•Yvonne Greenstreet•STAT Summit•Greenstreet
Resolution / Starting Odds
Pfizer • 25%
Ionis Pharmaceuticals • 25%
Eidos Therapeutics • 25%
Other • 25%
Market analysis reports from reputable biotech industry analysts
Story
Alnylam Submits Regulatory Application for Vutrisiran, Predicts Multibillion-Dollar Product with 60% Success Rate
Oct 17, 2024, 01:30 PM
Alnylam Pharmaceuticals has submitted a regulatory application to the European Medicines Agency for its drug Vutrisiran, aimed at treating ATTR amyloidosis with cardiomyopathy. The submission reflects the company's strategic focus on expanding its product offerings in the competitive biotech landscape. Alnylam's CEO, Yvonne Greenstreet, expressed confidence in the drug's potential, predicting it could become a multibillion-dollar product despite rising competition. At the recent STAT Summit, Greenstreet highlighted a 60% probability of success for their RNAi drug development programs, emphasizing the importance of providing quality therapeutic options to stimulate diagnosis rates for rare conditions. The company, co-founded by former CEO J. Maraganore, is positioned to be a leading player in the biotech sector.
View original story
Similar markets
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Vutrisiran leads • 25%
Acoramidis leads • 25%
Both have equal market share • 25%
Neither has significant market share • 25%
Market leader • 33%
Second place • 33%
Third place or lower • 33%
Yes • 50%
No • 50%
FDA approval • 25%
New clinical trial results • 25%
Partnership with another company • 25%
No major announcement • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Vutrisiran shows superior results • 25%
Acoramidis shows superior results • 25%
Both show comparable results • 25%
Neither shows significant improvement • 25%
Exceeds $1 billion in sales • 25%
Between $500 million and $1 billion in sales • 25%
Between $100 million and $500 million in sales • 25%
Less than $100 million in sales • 25%
Less than 20% • 33%
20% to 40% • 33%
More than 40% • 33%